Cost-effectiveness of Chronic Hepatitis C Treatment with Thymosin Alpha-1

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C

“…A total of 297 unique references were retrieved. Forty‐nine studies [12–60] met the inclusion criteria, including seven HTA reports [15,28,39,41,45,50,59] and one technology appraisal [33] assessing the cost‐effectiveness of antiviral therapy with interferon/peginterferon alone or in combination with ribavirin in patients with CHC.…”

“…Twelve studies [16,17,23,34,37,41,47,51,56,58–60] evaluated the cost‐effectiveness of interferon plus ribavirin in treatment‐naïve patients with CHC, and three studies [27,36,55] in interferon‐nonresponders or ‐relapsers. Twenty‐one studies [12,14,15,18,22,25,26,30,31,35,38,39,44–46,48,50,52–54,57,59] evaluated the cost‐effectiveness of peginterferon plus ribavirin. Among those, 16 studies [12,14,15,18,31,35,39,45,46,48,50,52–54,57,59] evaluated treatment‐naïve patients and five studies evaluated other populations such as interferon‐nonresponders/relapsers [22], patients with HIV–HCV coinfection [26,30], intravenous drug users (IDUs) [38] and patients with persistently normal ALT levels [25].…”

“…Several studies focused on specific settings or patient groups (Table 4). One study conducted in Mexico reported retreatment with peginterferon plus ribavirin in patients who had been previously treated with interferon plus ribavirin and did not respond or relapsed to be cost saving, when compared to no treatment [22].…”

Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C

“…For example, after costs were converted to a common currency and year, studies from eight different country perspectives provided the lowest costs for at least one health state: Germany [41], Italy [44], Japan [31], Spain [34], Sweden [35], Taiwan [28], the United Kingdom [22,37,38], and the United States [29,45,48]. Studies from seven different countries provided the highest costs for at least one health state: Japan [26,31], Mexico [19], Spain [18], Sweden [17], Switzerland [32], the United Kingdom [24,36], and the United States [15,29,33,45].…”

“…For example, of the 34 studies included in this review, 11 different country perspectives are represented (see Appendix Table 2 [18,34], Belgium [20], Mexico [19], Sweden [35], Italy [44], the United Kingdom [22,36,43], and the United States [29,33,[45][46][47]. The utilities of Siebert et al [39,63] have been incorporated into studies from Belgium [21], Mexico [19], Sweden [17], Japan [31], Taiwan [28] and Germany [39 -42].…”